Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

JWK002

Phase 1Small molecule

WWest China Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinoschisisRecruiting

RetinoschisisPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2033

Phase 1Recruiting

Retinoschisis

NCT06345898

Clinical

Trials by Indication[1]

Retinoschisis1 trial

Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)

Recruiting·WWest China Hospital·Phase 1·NCT06345898·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JWK002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JWK002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JWK002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWest China Hospital

Related News